| Assay ID | Title | Year | Journal | Article |
|---|
| AID344776 | Antitumor activity against human MOLM13 cells xenografted in SCID mouse assessed as minimal regressive tumor volume ratio at 200 mg/kg, po bid treated for 5 days measured after 10 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344782 | Antitumor activity against human MOLM13 cells xenografted in po dosed SCID mouse assessed as tumor volume ratio administered bid for 5 days | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344768 | Antiproliferative activity against human HMC1 cells expressing FLT3-delta599 mutant after 72 hrs by WST-1 assay | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344775 | Antitumor activity against human MOLM13 cells xenografted in SCID mouse assessed as minimal regressive tumor volume ratio at 100 mg/kg, po bid treated for 5 days measured after 4 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344779 | Toxicity to human MOLM13 cells xenografted SCID mouse assessed as mortality at 50 mg/kg, po bid after 5 days | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344774 | Antitumor activity against human MOLM13 cells xenografted in SCID mouse assessed as minimal tumor volume ratio at 100 mg/kg, po bid treated for 5 days measured after 10 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344767 | Metabolic stability in human liver microsomes assessed as intrinsic clearance | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344781 | Toxicity to human MOLM13 cells xenografted SCID mouse assessed as mortality at 200 mg/kg, po bid after 5 days | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344773 | Antitumor activity against human MOLM13 cells xenografted in SCID mouse assessed as tumor volume ratio at 200 mg/kg, po bid treated for 5 days measured after 10 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344772 | Antitumor activity against human MOLM13 cells xenografted in SCID mouse assessed as minimal tumor volume ratio at 100 mg/kg, po bid treated for 5 days measured after 7 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344769 | Antiproliferative activity against human HMC1 cells expressing FLT-D835Y mutant after 72 hrs by WST-1 assay | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344784 | Toxicity to human MOLM13 cells xenografted SCID mouse assessed as body weight loss at 200 mg/kg, po bid after 5 days | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344780 | Toxicity to human MOLM13 cells xenografted SCID mouse assessed as mortality at 100 mg/kg, po bid after 5 days | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344766 | Antiproliferative activity against human MOLM13 cells after 72 hrs by WST-1 assay | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344783 | Antitumor activity against human MOLM13 cells xenografted in po dosed SCID mouse assessed as regression tumor volume ratio administered bid for 5 days | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344770 | Antiproliferative activity against human ML1 cells after 72 hrs by WST-1 assay | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |